Next Generation RNA/Protein-Carrying Vector With Pleiotropic Activity

Area of Science:

• Virology
• Molecular Biology
• Vaccinology

Background:

• Human parainfluenza virus type 2 (hPIV2) is a common cause of infantile colds, possessing a gene expression system suitable for modification.
• The viral envelope of hPIV2 can be engineered to display foreign proteins, offering potential for novel therapeutic applications.

Purpose of the Study:

• To develop a non-propagative RNA/protein-carrying vector, termed BC-PIV, by genetically modifying hPIV2.
• To evaluate BC-PIV's capacity for delivering exogenous genes and proteins, and its potential as a vaccine vector and anti-tumor agent.

Main Methods:

• BC-PIV was created by deleting the F gene from hPIV2, rendering it non-replicative in standard cells but propagative in engineered Vero/BC-F packaging cells.
• Exogenous genes were inserted into the BC-PIV RNA genome, and foreign proteins (e.g., M2e, Ebola GP, SARS-CoV-2 spike) were incorporated into the viral envelope.
• The immunogenicity of delivered proteins was assessed by measuring neutralizing antibody induction in animal models.

Main Results:

• BC-PIV successfully delivered exogenous genes and proteins, including viral spike proteins, into target cells.
• Incorporation of Ebola GP and SARS-CoV-2 spike proteins into BC-PIV efficiently induced neutralizing antibodies against these viruses.
• BC-PIV demonstrated potential as a vaccine vector and for anti-tumor virus applications.

Conclusions:

• BC-PIV is a versatile, non-replicating viral vector capable of delivering both genetic material and proteins.
• The vector shows significant promise for developing new vaccines against infectious diseases and for cancer therapy.